RU2005119309A - Способ перитонеального диализа - Google Patents
Способ перитонеального диализа Download PDFInfo
- Publication number
- RU2005119309A RU2005119309A RU2005119309/15A RU2005119309A RU2005119309A RU 2005119309 A RU2005119309 A RU 2005119309A RU 2005119309/15 A RU2005119309/15 A RU 2005119309/15A RU 2005119309 A RU2005119309 A RU 2005119309A RU 2005119309 A RU2005119309 A RU 2005119309A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- adenosine triphosphate
- peritoneal
- glucose
- dialysate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Claims (20)
1. Перитонеальный диализат, содержащий аденозинтрифосфат или его соль.
2. Перитонеальный диализат по п.1, дополнительно содержащий глюкозу и электролит.
3. Профилактическое или терапевтическое средство для лечения повреждений брюшины, включающее аденозинтрифосфат или его соль в качестве активного ингредиента.
4. Средство для лечения клеточных повреждений, вызванных сахаром, включающее аденозинтрифосфат или его соль в качестве активного ингредиента.
5. Средство по п.4, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
6. Применение аденозинтрифосфата или его соли для изготовления перитонеального диализата.
7. Применение по п.6, где перитонеальный диализат, дополнительно, содержит глюкозу и электролит.
8. Применение аденозинтрифосфата или его соли для изготовления профилактического или терапевтического средства для лечения повреждения брюшины.
9. Применение аденозинтрифосфата или его соли для изготовления средства для лечения клеточных повреждений, вызванных сахаром.
10. Применение по п.9, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
11. Способ перитонеального диализа, отличающийся тем, что предусматривает применение диализата, содержащего аденозинтрифосфат или его соль в эффективном количестве.
12. Способ перитонеального диализа по п.11, содержащий внутрибрюшинное введение диализата, содержащего эффективное количество аденозинтрифосфата или его соли, через катетер, имплантированный в брюшную полость пациента, страдающего почечным заболеванием.
13. Способ перитонеального диализа по п.11 или 12, где содержание аденозинтрифосфата или его соли в диализате составляет от 10 до 5000 мкМ.
14. Способ перитонеального диализа по п.11 или 12, где диализат, дополнительно, включает глюкозу и электролит.
15. Способ перитонеального диализа по п.14, где содержание глюкозы составляет от 1000 до 4000 мг/дкл.
16. Способ перитонеального диализа по п.11, содержащий внутрибрюшинное введение через катетер, имплантированный в брюшную полость пациенту, страдающему почечным заболеванием, диализата, содержащего эффективное количество аденозинтрифосфата или его соли и физиологический уровень глюкозы перед введением диализата, содержащего глюкозу в высокой концентрации.
17. Способ перитонеального диализа по п.16, где физиологическое содержание глюкозы составляет от 0,08 до 0,16% (мас./об.), а высокое содержание глюкозы составляет от 1000 до 4000 мг/дкл.
18. Способ лечения повреждения брюшины, отличающийся тем, что вводят аденозинтрифосфат или его соль в эффективном количестве.
19. Способ лечения клеточного повреждения, вызванного сахаром, отличающийся тем, что вводят аденозинтрифосфат или его соль в эффективном количестве.
20. Способ по п.19, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42798002P | 2002-11-21 | 2002-11-21 | |
| US60/427,980 | 2002-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005119309A true RU2005119309A (ru) | 2006-01-20 |
| RU2353400C2 RU2353400C2 (ru) | 2009-04-27 |
Family
ID=32326623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005119309/15A RU2353400C2 (ru) | 2002-11-21 | 2003-11-20 | Способ перитонеального диализа |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8222229B2 (ru) |
| EP (1) | EP1563858A4 (ru) |
| JP (1) | JP4463687B2 (ru) |
| KR (1) | KR101057082B1 (ru) |
| CN (1) | CN1713926B (ru) |
| AU (2) | AU2003284594B2 (ru) |
| CA (1) | CA2506704C (ru) |
| HK (1) | HK1082441A1 (ru) |
| NZ (1) | NZ539796A (ru) |
| RU (1) | RU2353400C2 (ru) |
| WO (1) | WO2004045679A1 (ru) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235589B2 (en) * | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
| WO2008106702A1 (en) | 2007-03-02 | 2008-09-12 | Zytoprotec Gmbh | Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue |
| TW200936619A (en) | 2007-11-15 | 2009-09-01 | Univation Tech Llc | Polymerization catalysts, methods of making, methods of using, and polyolefin products made therefrom |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| ES2365429B1 (es) * | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
| EP2609116A1 (en) | 2010-08-26 | 2013-07-03 | Agrosavfe N.V. | Insect binding antibodies |
| US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
| SG190429A1 (en) | 2010-11-30 | 2013-06-28 | Univation Tech Llc | Catalyst composition having improved flow characteristics and methods of making and using the same |
| US8742041B2 (en) | 2010-11-30 | 2014-06-03 | Univation Technologies, Llc | Processes for the polymerization of olefins with extracted metal carboxylate salts |
| WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| CN103347905B (zh) | 2010-12-22 | 2015-12-16 | 尤尼威蒂恩技术有限责任公司 | 用于聚烯烃聚合方法的添加剂 |
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| GB2503162B (en) | 2011-03-23 | 2018-08-22 | Nxstage Medical Inc | Peritoneal dialysis systems and devices |
| CN103534279B (zh) | 2011-05-13 | 2016-08-17 | 尤尼威蒂恩技术有限责任公司 | 喷雾干燥的催化剂组合物及使用其的聚合方法 |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| ES2798272T3 (es) | 2011-11-08 | 2020-12-10 | Univation Tech Llc | Métodos de preparación de un sistema catalítico |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| ES2768180T3 (es) | 2013-01-30 | 2020-06-22 | Univation Tech Llc | Procedimientos para producir composiciones catalíticas con fluidez mejorada |
| CN114957529A (zh) | 2014-04-02 | 2022-08-30 | 尤尼威蒂恩技术有限责任公司 | 连续性组合物及其制备和使用方法 |
| CN112807074A (zh) | 2014-05-12 | 2021-05-18 | 弗吉尼亚暨州立大学知识产权公司 | 电穿孔系统 |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| EP3247547B1 (en) | 2015-01-21 | 2023-03-22 | Univation Technologies, LLC | Methods for gel reduction in polyolefins |
| SG11201705607QA (en) | 2015-01-21 | 2017-08-30 | Univation Tech Llc | Methods for controlling polymer chain scission |
| CN107428875B (zh) | 2015-03-10 | 2021-02-26 | 尤尼威蒂恩技术有限责任公司 | 喷雾干燥催化剂组合物、制备方法以及在烯烃聚合工艺中的用途 |
| US10533063B2 (en) | 2015-04-20 | 2020-01-14 | Exxonmobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
| SG11201708626SA (en) | 2015-04-27 | 2017-11-29 | Univation Tech Llc | Supported catalyst compositions having improved flow properties and preparation thereof |
| DE102015007842A1 (de) * | 2015-06-18 | 2016-12-22 | Fresenius Medical Care Deutschland Gmbh | Dialyselösung |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| WO2018151903A1 (en) | 2017-02-20 | 2018-08-23 | Exxonmobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
| EP3641850B1 (en) | 2017-06-24 | 2024-10-09 | NxStage Medical Inc. | Peritoneal dialysis fluid preparation systems |
| EP3661981A1 (en) | 2017-08-04 | 2020-06-10 | ExxonMobil Chemical Patents Inc. | Polyethylene compositions and films prepared therefrom |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US11872337B2 (en) | 2018-02-28 | 2024-01-16 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| SG11202010442QA (en) | 2018-04-26 | 2020-11-27 | Exxonmobil Chemical Patents Inc | Non-coordinating anion type activators containing cation having large alkyl groups |
| EP3810666B1 (en) | 2018-06-19 | 2024-07-31 | ExxonMobil Chemical Patents Inc. | Polyethylene compositions and films prepared therefrom |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| WO2021119089A1 (en) | 2019-12-11 | 2021-06-17 | Exxonmobil Chemical Patents Inc. | Processes for introduction of liquid activators in olefin polymerization reactions |
| US20230141606A1 (en) | 2020-03-25 | 2023-05-11 | Exxonmobil Chemical Patents Inc. | Alkylation of Transition Metal Coordination Catalyst Complexes |
| WO2021262838A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | Copolymers composed of ethylene, a-olefin, non-conjugated diene, and substituted styrene and articles therefrom |
| WO2021262842A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | COPOLYMERS OF ETHYLENE, α-OLEFIN, NON-CONJUGATED DIENE, AND ARYL-SUBSTITUTED CYCLOALKENE, METHODS TO PRODUCE, BLENDS, AND ARTICLES THEREFROM |
| WO2022035484A1 (en) | 2020-08-10 | 2022-02-17 | Exxonmobil Chemical Patents Inc. | Methods for delivery of non-aromatic solutions to polymerization reactors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| US5679650A (en) | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| DE69406649T2 (de) | 1993-02-10 | 1998-03-05 | Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire | N-alkyl-2-substituierte atp-analoge |
| US5547942A (en) * | 1994-01-04 | 1996-08-20 | Rapaport; Eliezer | Method of treatment of diabetes mellitus by administration of adenosine 5'-t |
| JPH09143063A (ja) | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| JP3623294B2 (ja) * | 1995-11-28 | 2005-02-23 | 株式会社新素材総合研究所 | 電解質液が収容された医療用容器及びその製造方法 |
| WO1999009953A1 (fr) * | 1997-08-22 | 1999-03-04 | Shimizu Pharmaceutical Co., Ltd. | Preparation contenant du glucose |
| KR100478181B1 (ko) * | 1998-08-24 | 2005-03-23 | 토카이 유니버시티 에듀케이셔널시스템 | 카르보닐 스트레스상태 개선제 및 복막투석액 |
| US6309673B1 (en) * | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
-
2003
- 2003-11-20 CA CA2506704A patent/CA2506704C/en not_active Expired - Fee Related
- 2003-11-20 JP JP2004553210A patent/JP4463687B2/ja not_active Expired - Fee Related
- 2003-11-20 US US10/533,538 patent/US8222229B2/en not_active Expired - Fee Related
- 2003-11-20 CN CN2003801036528A patent/CN1713926B/zh not_active Expired - Fee Related
- 2003-11-20 AU AU2003284594A patent/AU2003284594B2/en not_active Ceased
- 2003-11-20 KR KR1020057008224A patent/KR101057082B1/ko not_active IP Right Cessation
- 2003-11-20 NZ NZ539796A patent/NZ539796A/en not_active IP Right Cessation
- 2003-11-20 RU RU2005119309/15A patent/RU2353400C2/ru not_active IP Right Cessation
- 2003-11-20 WO PCT/JP2003/014790 patent/WO2004045679A1/ja active Application Filing
- 2003-11-20 EP EP03774083A patent/EP1563858A4/en not_active Withdrawn
-
2006
- 2006-03-13 HK HK06103148.9A patent/HK1082441A1/xx not_active IP Right Cessation
-
2008
- 2008-12-09 AU AU2008255178A patent/AU2008255178B2/en not_active Ceased
-
2009
- 2009-03-30 US US12/414,312 patent/US20090186850A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4463687B2 (ja) | 2010-05-19 |
| HK1082441A1 (en) | 2006-06-09 |
| CN1713926B (zh) | 2010-12-22 |
| US20060019925A1 (en) | 2006-01-26 |
| JPWO2004045679A1 (ja) | 2006-03-16 |
| US8222229B2 (en) | 2012-07-17 |
| KR101057082B1 (ko) | 2011-08-16 |
| KR20050075381A (ko) | 2005-07-20 |
| NZ539796A (en) | 2006-11-30 |
| AU2003284594A1 (en) | 2004-06-15 |
| CA2506704A1 (en) | 2004-06-03 |
| WO2004045679A1 (ja) | 2004-06-03 |
| CN1713926A (zh) | 2005-12-28 |
| AU2008255178A1 (en) | 2009-01-08 |
| AU2008255178B2 (en) | 2010-07-08 |
| CA2506704C (en) | 2013-06-25 |
| EP1563858A4 (en) | 2010-09-29 |
| RU2353400C2 (ru) | 2009-04-27 |
| US20090186850A1 (en) | 2009-07-23 |
| AU2003284594B2 (en) | 2009-01-15 |
| EP1563858A1 (en) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005119309A (ru) | Способ перитонеального диализа | |
| ES2380430T5 (es) | Soluciones a base de bicarbonato para tratamientos de diálisis | |
| EP1753437B1 (en) | Bicarbonate-based peritoneal dialysis solutions | |
| US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
| US6492336B1 (en) | Peritoneal dialysis fluid | |
| JP2009051850A (ja) | Ｌ−カルノシンを含む腎不全の処置用の組成物 | |
| JP4061775B2 (ja) | アルブミン含有腹膜透析液 | |
| JP7034933B2 (ja) | 透析濃縮液 | |
| Anderson et al. | The treatment of pulmonary edema in the absence of renal function: a role for sorbitol and furosemide | |
| Page et al. | Multiple-dose pharmacokinetics of ketoconazole administered orally to gopher tortoises (Gopherus polyphemus) | |
| JPH1171273A (ja) | 腹膜透析液 | |
| JPH01151462A (ja) | 腹膜灌流液 | |
| Cope | The chemical aspects of burn treatment | |
| Sam et al. | Sildenafil in dialysis patients | |
| RU2411046C2 (ru) | Способ детоксикации у больных перитонитом | |
| Ronco et al. | Rhabdomyolysis | |
| MXPA98005326A (en) | Compositions for the treatment of renal failure, comprising l-carnosine | |
| UA75211C2 (en) | Method for treatment of liver affected by alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151121 |